DocumentsDate added
ORIGINAL ARTICLE
Zhang Bei-Bei1,He Jin-Lian2,Bei Yu2,Zhang You-Ying1,Huang Ya-Dong1,2,Xiang Qi1,2*
1 College of Pharmacy, Jinan University, Guangzhou 510632, P.R. China
2 Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, P.R. China
Address reprint requests to
* Xiang Qi, Associate Professor, College of Pharmacy, Jinan University, Guangzhou 510632, P.R. China
Article citation: Bei-Bei Z, Jin-Lian H, Yu B,You-Ying Z, Ya-Dong H, Qi X. Safety evaluation of GP-EGF lyophilised powder.J Pharm Biomed Sci 2016;06(05):295–300.Available at www.jpbms.info
ABSTRACT
To clarify the safe risks related to the use of GP-EGF lyophilised powder (GELP), acute toxicity test, dermal allergy test, dermal irritation test, and subchronic toxicological test were evaluated according to the guideline for hygienic standard for cosmetics (2007). In acute toxicity tests using guinea pigs, there was no treatment-related mortality, clinical signs of toxicity, body weight changes and gross findings at a dose level of 2,000 mg·kg−1·d−1. Similarly, dermal allergy test using guinea pigs and dermal irritation test using rabbits revealed no mortality, clinical signs of toxicity and a corrosion reaction on the skin. In the subchronic study, no death or clinical signs, or abnormal haematological, biochemical and histopathological changes were found in rats after receiving, by the concentration in
56 mg·mL−1·d−1, 112 mg·mL−1·d−1 of GELP for 90 days. Our findings indicated that GELP is relatively safe since it did not induce an acute toxicity test, dermal allergy test, dermal irritation test and subchronic toxicological test.
KEYWORDS EGF, GP-EGF lyophilised powder (GELP), acute toxicity test, dermal allergy test, dermal irritation test, subchronic toxicological test.
REFERENCES
1.Hashimoto K. Regulation of keratinocyte function by growth factors. J Dermatol Sci. 2000;24(1):S46–S50.
2.Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T, Sudo K, et al. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes.J Biol Chem. 1994;269(31):20060–6.
3.Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. 1999;59(16):3915–8.
4.Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al. Bypassing cellular EGF receptor dependence through epithelial-to- mesenchymal-like transitions. Clin Exp Metastasis. 2008;25(6):685–93.
5.Bhat FA, Sharmila G, Balakrishnan S, Arunkumar R, Elumalai P, Suganya S, et al. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem.2014;25(11):1132–9.
6.Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–58.
7.Cheng JC, Klausen C, Leung PC. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013;329(2):197–206.
8.Cheng JC, Auersperg N, Leung PC. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS ONE. 2012;7(3):e34071.
9.Ficheux AS, Chevillotte G, Wesolek N, Morisset T, Dornic N, Bernard A, et al. Consumption of cosmetic products by the French population second part: amount data. Food Chem Toxicol. 2016;90:130–41.
10.Ma’or Z, Halicz L, Portugal-Cohen M, Russo MZ, Robino F,Vanhaecke T, et al. Safety evaluation of traces of nickel and chrome in cosmetics: the case of Dead Sea mud. Regul Toxicol Pharmacol. 2015;73(3):797–801.
11.Hrabchak C, Rouleau J, Moss I, Woodhouse K, Akens M, Bellingham C, et al. Assessment of biocompatibility and initial evaluation of genipin cross-linked elastin-like polypeptides in the treatment of an osteochondral knee defect in rabbits. Acta biomater. 2010;6(6):2108–15.
12.Viswanath L, Reddy KBKM, Vidyasagar M, Koteshwar R, Shenoy AM, Thimmaiah N, et al. A phase IIb, 4 arm open-label, randomized trial, to assess the safety and efficacy of concurrent hR3 monoclonal antibody against EGF-receptor with chemoradiation therapy or with radiation therapy in patients with advanced (stage III–IVa), inoperable head and neck cancer. Int J Rad Oncol Biol Phys. 2009;75(3):S15–S6.
13.Mancebo A, Casacó A, González B, Ledón N, Sorlozabal J,León A, et al. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity. Vaccine. 2012;30(22):3329–38.
14.Wang Y, Liu P, Qiu L, Sun Y, Zhu M, Gu L, et al. Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials. 2013;34(16):4068–77.
15.Ko H, Kim JM, Kim SJ, Shim SH, Ha CH, Chang HI. Induction of apoptosis by genipin inhibits cell proliferation in AGS human gastric cancer cells via Egr1/p21 signaling pathway. Bioorg Med Chem Lett. 2015;25(19):4191–6.
16.Fiamingo A, Campana-Filho SP. Structure, morphology and properties of genipin-crosslinked carboxymethylchitosan porous membranes. Carbohydr Polym. 2016;143:155–63.
17.Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell.2000;103(2):211–25.
18.Cañón-Beltrán K, Cajas Y, Garcia-Garcia R, Lorenzo P, Carrera R, Rebollar P, et al. Effect of epidermal growth factor on nuclear and cytoplasmic in vitro maturation of guinea pig oocytes. Anim Reprod. 2015;12(3):793.
19.Madhukar BV, Brewster DW, Matsumura F. Effects of in vivo-administered 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor binding of epidermal growth factor in the hepatic plasma membrane of rat, guinea pig, mouse, and hamster. Proc Natl Acad Sci U S A. 1984;81(23):7407–11.
20.Kim JS, McKinnis VS, Nawrocki A, White SR. Stimulation of migration and wound repair of guinea-pig airway epithelial cells in response to epidermal growth factor. Am J Respir Cell Mol Biol. 1998;18(1):66–74.
21.Mondain M, Ryan A. Epidermal growth factor and basic fibroblast growth factor are induced in guinea-pig tympanic membrane following traumatic perforation. Acta Otolaryngol. 1995;115(1): 50–4.
22.Koo HJ, Lim KH, Jung HJ, Park EH. Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J Ethnopharmacol. 2006;103(3):496–500.
23.Wang M, Corpuz CC. Effects of scleral cross-linking using genipin on the process of form-deprivation myopia in the guinea pig: a randomized controlled experimental study. BMC Ophthalmol.2015;15(1):89.
24.Moore M, Adams A. Calcification resistance, biostability, and low immunogenic potential of porcine heart valves modified by dye-mediated photooxidation. J Biomed Mater Res.2001;56(1):24–30.
25.Raymond G, Jumblatt M, Bartels S, Neufeld A. Rabbit corneal endothelial cells in vitro: effects of EGF. Invest Ophthalmol Vis Sci. 1986;27(4):474–9.
26.Lee JH, Baek HR, Lee KM, Lee DY, Lee AY. Enhanced osteoinductivity of recombinant human bone morphogenetic protein-2 in combination with epidermal growth factor in a rabbit tibial defect model. Growth Factors. 2015;33(1):31–9.
27.Hou Y, Tsai SY, Lai P, Chen Y, Chao P. Metabolism and pharmacokinetics of genipin and geniposide in rats. Food Chem Toxicol. 2008;46(8):2764–9.
28.Nam KN, Choi YS, Jung HJ, Park GH, Park JM, Moon SK, et al. Genipin inhibits the inflammatory response of rat brain microglial cells. Int Immunopharmacol. 2010;10(4):493–9.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgments: The authors would like to thank their colleague Su Wan who works in the institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine in Jinan University for the supplement of GELP and EGF.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Amit Agrawal*,Sipra Lenka,Pratima Mishra
Department of Obstetric and Gynaecology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to
*Dr. Amit Agrawal,
Department of Obstetrics and Gynaecology, Hi-Tech Medical College and Hospital,Bhubaneshwar, Orissa, India
Article citation: Agrawal A, Lenka S,Mishra P. Study of age, parity and contraceptive use as risk factors in cervical carcinoma. J Pharm Biomed Sci 2016;06(05):293–294.Available at www.jpbms.info
Abstract
Background Cervix is one of the most common genital malignancy leading to increased mortality in women, Early diagnosis by different screening modalities can reduce the mortality. Identification of high risk group and putting them for screening can reduce disease burden.
Materials and Methods The study of age, parity and contraceptive use as risk factors in cervical carcinoma were carried out from patients attending the O & G OPD in Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India during the period from January 2014 to January 2015.
Results The study was conducted on 100 cases in Hi-Tech Medical College and Hospital with features of unhealthy cervix, and the results were analysed.
Conclusion In this study, different risk factors like age of the patient, parity and the use of contraceptive methods have been studied and analysed.
KEYWORDS unhealthy cervix, parity, contraception in CIN
REFERENCES
1.Kushtagi P, Fernandez P. Significance of persistent inflammatory, cervical smears in sexually active women of reproductive age. J Obstet Gynaecol India. 2002;52(1):124–6.
2.Maiman M, Fruchter RG, Sedlis A, Feldman J, Chen P, Burk RD,et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynaecol Oncol. 1998;68(3):233–9.
3.Schmauz R, Okong P, de Villiers EM, Dennin R, Brade L, Lwanga SK, et al. Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa. Int J Cancer. 1989;43:805–9.
4.Vaidya A. Comparison of Pap test among high and non-high risk female. Kathmandu Univ Med J. 2003;1(1):8–13.
5.Sukhpreet LS, Nayana AD, Murari SN. Comparison of colposcopy and pap smear: sensitivity, specificity and predictive values. BHJ.2000;42:4.
6.Verreault R, Chu J, Mandelson M, Shy K. A case–control study of diet and invasive cervical cancer. Int J Cancer. 1989;43:1050–4.
7.Yarandi F, Izadi MN, Mirashrafi F, Eftekhar Z. Colposcopic and histologic findings in women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Aust N Z J Obstet Gynaecol. 2004;44(6):514–6.
Research article
Chaopeng Wang1,Guangming Chen1,Jiefang Wang1,Hengrui Liu1, Yinquan Xiong1,Panpan Wang2, Li Yang1,Xiaofeng Zhu2,Ronghua Zhang1*
1 Jinan University College of Pharmacy,Guangzhou 510632, China
2 First Affiliated Hospital of Jinan University,Jinan University, Guangzhou 510632, P.R. China
Address reprint requests to
*Ronghua Zhang, Jinan University College of Pharmacy, Guangzhou 510632, China
Article citation: Wang C, Chen G, Wang J, Liu H, Xiong Y, Wang P, Yang L, Zhu X,Zhang R. Effect of Herba Epimedium extract on bone mineral density and microstructure in ovariectomised rat. J Pharm Biomed Sci 2016;06(05):275–278.Available at www.jpbms.info
ABSTRACT
Aim To observe the effects of Herba Epimedium (HE) extract on bone mineral density(BMD) and microstructure in ovariectomised (OVX) rat.
Methods A total of 84 female Sprague–Dawley rats of 3-month-old were randomly divided into OVX group (n = 70) and sham group (n = 14). The osteoporotic model was established by ovariectomy. Twelve weeks after ovariectomy, when the osteoporosis (OP) was successfully affirmed by the BMD, the rats in OVX group was randomly divided into OVX group (n = 14),low-dose HE group (n = 14), middle-dose HE group (n = 14), high-dose HE group (n = 14) and positive group (n = 14). The BMD was measured by dual-energy X-ray. The microstructure of the bone was observed by micro‑computed tomography.
Results Twelve weeks after ovariectomy, the BMD of femur of rats in OVX group was significantly lower than that of in sham group (P < 0.05). After 12 weeks of treatment, the
BMD of femurs of rats in HE and positive groups were significantly higher than that in OVX group (P < 0.05), also the bone microstructure of rats in HE group has been recovered as the positive group.
Conclusion HE has strong therapeutical effect on OP, can improve the BMD and microstructure of bones.
Acknowledgement: This work was supported by grants from the National Natural Science Foundation of China (81473509), the National Natural Science Foundation of China (81503384), the Cultivation and Innovation Fund for Scientific Research of Jinan University Youth Fund Project (no. 21612341) and the Fundamental Research Funds for the Central Universities (21614309).
References
1.Shan PF, Xian CJ, Li M, Xiang GD, Yuan LQ. Osteoporosis. Int J Endocrinol. 2013;2013:952858.
2.Reid IR. Osteoporosis treatment: focus on safety. Eur J Intern Med. 2013;24(8):691–697.
3.Gao SQ, Fu DX, Zhang HM. Advances in the study on the treatment of osteoporosis with Herba Epimedii and its compound prescriptions. China J Chin Mater Med. 1999;24:249–251.
4.Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci. 2015;126:57–68.
5.Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. J Clin Densitom. 2004;7:1–6.
6.Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Przegląd Menopauzalny. 2014;13(4):213–20.
7.Agata U, Park JH, Hattori S, Aikawa Y, Kakutani Y, Ezawa I, et al.The impact of different amounts of calcium intake on bone mass and arterial calcification in ovariectomized rats. J Nutr Sci Vitaminol (Tokyo). 2015;61(5):391–9.
8.Xiao HH, Fung CY, Mok SK, Wong KC, Ho MX, Wang XL, et al. Flavonoids from Herba Epimedii selectively activate estrogen receptor alpha (ERα) and stimulate ER-dependent osteoblastic functions in UMR-106 cells. J Steroid Biochem Mol Biol.2014;143:141–51.
9.Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–2261.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Letter to the Editor
Shubhankar Mishra1,T. V. Ram Kumar1,Ashok Kumar Biswas2*
1Department of Paediatrics, MKCG Medical College, Berhampur, Odisha, India
2Regional Medical Research Centre (ICMR),Port Blair, Andaman and Nicobar Islands,India
Address reprint requests to
*Dr. Ashok Kumar Biswas, MBBS, DPH,MS, Medical Scientist, Regional Medical Research Centre (Indian Council of Medical Research), Post Bag no. 13, Dollygunj,Port Blair South Andaman, Andaman and Nicobar Islands, 744101, India
Article citation: Mishra S, Kumar TVR,Biswas AK. Post-cyclone poisonings in paediatric age group: an abnormal demography. J Pharm Biomed Sci 2016;06(05):284–285.Available at www.jpbms.info
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research,patents and royalties through this collaborative
research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense
Original article
Gong Tian1†,Zhou Guifang1†,Ye Qiumian1,Kuang Jianyuan1,Ou Jinlai2,Xu Zhenxia1,Zhao Wen1,Li Sha1*
1 Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Department of Preparation, Sunshinelake Pharma Co., LTD., Shenzhen 523871,China
† Both the authors contributed equally to this work
Address reprint requests to
*Li Sha, Department of Pharmaceutics,College of Pharmacy, Jinan University,Guangzhou 510632, China
Article citation: Tian G, Guifang Z,Qiumian Y, Jianyuan K, Jinlai O, Zhenxia X,Wen Z, Sha L. In vitro anticancer activity of doxorubicin-loading pectin nanoparticles. J Pharm Biomed Sci 2016;06(05):338–342.Available at www.jpbms.info
BSTRACT
By using pectin (PEC) as carrier material and doxorubicin (DOX) as a model drug, the blank PEC nanoparticles (PEC-NPs) and the DOX-loading PEC nanoparticles (DOX-PEC-NPs) were prepared by microemulsification method and drug adsorption. The aim of this study is to investigate the anticancer activity of DOX-PEC-NPs in vitro to understand the advantages of PEC-NPs as an anticancer drug delivery system. The particle size, polydispersity index (PDI) and zeta potential of PEC-NPs were (276.80 ± 2.80) nm, (0.140 ± 0.014) and (−19.83 ± 0.21) mV, while those of DOX-PEC-NPs were (283.73 ± 3.26) nm, (0.157 ± 0.034) and (−18.00 ± 0.44) mV. The entrapment efficiency (EE%) and drug-loading rate (LR%) of DOX-PEC-NPs were (92.10 ± 0.60)% and (18.72 ± 0.10)%, respectively. Using an MTT assay, the DOX-PEC-NPs were proved to greatly inhibit the viability of MDAMB-231 cells, A549 cells and NCI-H1299 cells, and the anticancer activity was higher than that of the DOX solution in these cells. The PEC-NPs had no cytotoxicity against the three tested cells. An inverted fluorescence microscope and flow cytometry were used to observe the intracellular uptake of DOX. The DOX-PEC-NPs resulted in faster and more DOX uptake than DOX solution in the tested cells. The results indicated that the PEC-NPs may be a potential anticancer drug delivery system which could reduce the dose and increase the activity of anticancer drugs.
KEYWORDS doxorubicin, pectin, nanoparticle, anticancer activity.
REFERENCES
1.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell.2000;100:57–70.
2.Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331–41.
3.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
4.Zhang N, Klegerman ME, Deng H, Shi Y, Golunski E, An Z.Trastuzumab–doxorubicin conjugate provides enhanced anticancer potency and reduced cardiotoxicity. J Cancer Ther. 2013;04:308–22.
5.Lei H, Wang X, Wu C. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations. J Mol Graph Model. 2012;38:279–89.
6.Evans AR, Miriyala S, St Clair DK, Butterfield DA, Robinson RA.Global effects of adriamycin treatment on mouse splenic protein levels. J Proteome Res. 2012;11:1054–64.
7.Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 2010;4:589–94.
8.Raj R, Das S. Prospects of bacteriotherapy with nanotechnology in nanoparticledrug conjugation approach for cancer therapy. Curr Med Chem. 2016;23:1477–94.
9.Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett. 2012;327:111–22.
10.Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007;96:1315–9.
11.Zhuang Y, Deng H, Su Y, He L, Wang R, Tong G, et al. Aptamerfunctionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapy. Biomacromolecules. 2016 [Epub ahead of print].
12.d’Ayala GG, Malinconico M, Laurienzo P. Marine derived polysaccharides for biomedical applications: chemical modification approaches. Molecules. 2008;13:2069–106.
13.Yuan Q, Venkatasubramanian R, Hein S, Misra RD. A stimulus- responsive magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-copolymer. Acta biomater. 2008;4:1024–37.
14.Liu L, Fishman ML, Hicks KB. Pectin in controlled drug delivery: a review. Cellulose. 2006;14:15–24.
15.Katav T, Liu L, Traitel T, Goldbart R, Wolfson M, Kost J. Modified pectin-based carrier for gene delivery: cellular barriers in gene delivery course. J Control Release. 2008;130:183–91.
16.Wen S, Ou J, Luo R, Liang W, OuYang P, Zeng F, et al. Preparation and release behavior of pectin nanoparticles loading doxorubicin. J Pharm Biomed Sci. 2015;5:385–93.
17.Ou J, Hong B, Ye X, Feng C, Gong T, Li S. Preparation and anti-tumor activity of doxorubicin-loading pectin nanoparticles in vitro. J Jinan Univ. 2014;35:330–6.
18.Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–8.
19. Yao F, Duan J, Wang Y, Zhang Y, Guo Y, Guo H, et al. Nanopore single-molecule analysis of DNA-doxorubicin interactions. Anal Chem. 2015;87:338–42.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of support: This research was supported by High Level University Construction Project (88015006).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.